Search Results - "Altorjay, I"

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis by Fickert, Peter, Hirschfield, Gideon M., Denk, Gerald, Marschall, Hanns-Ulrich, Altorjay, Istvan, Färkkilä, Martti, Schramm, Christoph, Spengler, Ulrich, Chapman, Roger, Bergquist, Annika, Schrumpf, Erik, Nevens, Frederik, Trivedi, Palak, Reiter, Florian P., Tornai, Istvan, Halilbasic, Emina, Greinwald, Roland, Pröls, Markus, Manns, Michael P., Trauner, Michael

“…[Display omitted] •There is an urgent need for novel drugs for PSC.•In this phase II clinical trial, norUDCA reduced serum ALP levels within 12weeks.•norUDCA’s…”
Get full text

Advanced biliary cannulation strategies in tertiary centers – analysis of 1871 native papilla cases from the Hungarian ERCP Registry by Pécsi, D., Gódi, Hegyi, P., Altorjay, I., Bakucz, T., Czakó, L., Kovács, G., Orbán-Szilágyi, î, Pakodi, F., Patai, î, Szepes, Z., Gyökeres, T., Fejes, R., Dubravcsik, Z., Vincze, î

Get full text

Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study by Trauner, M, Fickert, P, Hirschfield, G, Reiter, F, Altorjay, I, Marschall, H.U, Färkkilä, M, Schramm, C, Spengler, U, Chapman, R, Bergquist, A, Schrumpf, E, Nevens, F, Halilbasic, E, Greinwald, R, Proels, M, Manns, M.P

Get full text

ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients by Lakatos, P.L, Szamosi, T, Szilvasi, A, Molnar, E, Lakatos, L, Kovacs, A, Molnar, T, Altorjay, I, Papp, M, Tulassay, Z, Miheller, P, Papp, J, Tordai, A, Andrikovics, H

“…Abstract Background North American and European genome-wide association scans have identified ATG16L1 and IL23R as novel inflammatory bowel disease (IBD)…”
Get full text

NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease by Molnar, T, Hofner, P, Nagy, F, Lakatos, P.L, Fischer, S, Lakatos, L, Kovacs, A, Altorjay, I, Papp, M, Palatka, K, Demeter, P, Tulassay, Z, Nyari, T, Miheller, P, Papp, J, Mandi, Y, Lonovics, J

“…Abstract Background NOD1/CARD4, a member of the pattern-recognition receptor family, is a perfect candidate as a susceptibility gene for Crohn's disease. Since…”
Get full text

Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells by Altorjay, I, Veréb, Z, Serfozo, Z, Bacskai, I, Bátori, R, Erdodi, F, Udvardy, M, Sipka, S, Lányi, Á, Rajnavölgyi, É, Palatka, K

“…The aim of this study is to investigate the effect of sera obtained from patients of Crohn's disease treated by anti-TNF-alpha antibody (Infliximab) on the…”
Get more information

Esophageal replacement using cryopreserved tracheal graft by Juhász, Á., Szilágyi, A., Mikó, I., Altorjay, I., Kecskés, G., Altorjay, Á.

“…Esophageal replacement using artificial material is not a new concept. Prior experiences with prostheses, allografts and composite grafts have not proved…”
Get full text

Certolizumab Pegol for the Treatment of Crohn's Disease by Sandborn, William J, Feagan, Brian G, Stoinov, Simeon, Honiball, Pieter J, Rutgeerts, Paul, Mason, David, Bloomfield, Ralph, Schreiber, Stefan

“…In this randomized trial involving 662 patients with moderate-to-severe Crohn's disease, 23% of patients who were treated with certolizumab pegol (a pegylated…”
Get full text

Evaluation of hemostatic changes and blood antioxidant capacity in acute and chronic pancreatitis by Kerekes, L, Arkossy, P, Altorjay, I, Huszka, M, Kappelmayer, J, Tóth, P, Szentkereszty, Z, Sápy, P

“…We examined changes in hemostasis, in levels of total antioxidant capacity, and pancreatic enzymes (amylase, lipase) in patients with pancreatitis 1, 3 and 7…”
Get more information

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study by Reinisch, Walter, de Villiers, Williem, Bene, László, Simon, László, Rácz, István, Katz, Seymour, Altorjay, István, Feagan, Brian, Riff, Dennis, Bernstein, Charles N., Hommes, Daniel, Rutgeerts, Paul, Cortot, Antoine, Gaspari, Michael, Cheng, May, Pearce, Tillman, Sands, Bruce E.

“…Background: The safety and efficacy of fontolizumab, a humanized anti‐interferon gamma antibody, was investigated in patients with Crohn's disease (CD)…”
Get full text

Effect of L-arginine on in vitro plasmin-generation and fibrinogenolysis by Udvardy, M, Posán, E, Palatka, K, Altorjay, I, Harsfalvi, J

“…L-arginine has received much attention in numerous aspects of the regulation of vascular tone and haemostasis. L-arginine seems to be capable to bind to…”
Get full text

LB02 - Norursodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis: Results of a Phase II Dose Finding Study by Trauner, M., Fickert, P., Hirschfield, G., Reiter, F., Altorjay, I., Marschall, H.U., Färkkilä, M., Schramm, C., Spengler, U., Chapman, R., Bergquist, A., Schrumpf, E., Nevens, F., Halilbasic, E., Greinwald, R., Proels, M., Manns, M.P.

Get full text

nor Ursodeoxycholic acid improves cholestasis in primary sclerosing cholangitis by Fickert, Peter, Hirschfield, Gideon M, Denk, Gerald, Marschall, Hanns-Ulrich, Altorjay, Istvan, Färkkilä, Martti, Schramm, Christoph, Spengler, Ulrich, Chapman, Roger, Bergquist, Annika, Schrumpf, Erik, Nevens, Frederik, Trivedi, Palak, Reiter, Florian P, Tornai, Istvan, Halilbasic, Emina, Greinwald, Roland, Pröls, Markus, Manns, Michael P, Trauner, Michael

“…Graphical abstract…”
Get full text

Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins? by Lakatos, P. L., Altorjay, I., Mándi, Y., Lakatos, L., Tumpek, J., Kovacs, A., Molnar, T., Tulassay, Z., Miheller, P., Palatka, K., Szamosi, T., Fischer, S., Papp, J., Papp, M.

“…Antibodies against different microbial epitopes are associated with disease phenotype, may be of diagnostic importance and may reflect a loss of tolerance in…”
Get full text

Extensive resection of small intestine by ALTORJAY, I

Get more information

P436 Clinical course of ulcerative colitis according to the partial Mayo score based classification during two-year follow-up period: Result from a Hungarian multicenter IBD database by Nagy, F., Molnár, T., Farkas, K., Szepes, Z., Miheller, P., Tulassay, Z., Horvath, G., Ujszaszy, L., Palatka, K., Altorjay, I., Virányi, Z., Szepes, A., Nyari, T., Wittmann, T.

Get full text

Changes of spontaneous and induced platelet aggregation in the presence of a human endothelial cell monolayer by Altorjay, I, Kirchmaier, C M, Breddin, H K

“…A new, simple method has been developed for the investigation of platelet aggregation in the presence of a cultured confluent human endothelial cell monolayer,…”
Get more information

nor Ursodeoxycholic acid ( nor UDCA) improves cholestasis in primary sclerosing cholangitis (PSC) independent of ursodeoxycholic acid (UDCA) pre-treatment and response by Trauner, MH, Fickert, P, Hirschfield, G, Denk, G, Altorjay, I, Marschall, HU, Farkkila, MA, Schramm, C, Spengler, U, Chapman, RW, Bergquist, A, Schrumpf, E, Nevens, F, Halilbasic, E, Greinwald, R, Prols, M, Manns, MP

Get full text

Saliva level of ethynylestradiol in presence of ethynodiol diacetate after oral administration by Morvay, J, Altorjay, I, Sas, M

“…In the presence of ethynodiol diacetate the ethynylestradiol concentration in serum and saliva after oral administration was measured by a rapid…”
Get more information

Rapid radioimmunoassay (RIA) of ethynyloestradiol in body fluids by Morvay, J, Fotherby, K, Altorjay, I

Get more information